Dogwood Therapeutics

Name

Dogwood Therapeutics

Legal name

Dogwood Therapeutics, Inc.

Website

https://dwtx.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Pain Management, Anesthesia & Critical Care Drugs (HLAMAEAF)

Keywords

• Non-opioid analgesics
• Neuropathic pain drugs
• Chemotherapy-induced neuropathy
• Clinical-stage biopharmaceutical
• Sodium channel inhibitors

Headquarters

HQ city

Alpharetta

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue development-stage company. Once FDA-approved, plans to generate revenue through sales of prescription pharmaceuticals (Halneuron and SP16) distributed through pharmacy channels to cancer patients and healthcare providers.
2. Licensing Royalties and Milestone Payments: Partnership with PRIDCor Therapeutics for anti-viral candidates IMC-1 and IMC-2 entitles Dogwood to tiered royalties up to 15% on net sales, 9% of future capital raised by PRIDCor, and development/regulatory milestone payments with total potential value capped at $100 million.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing first-in-class, non-opioid therapeutics for chemotherapy-induced neuropathic pain (CINP) and chemotherapy-induced peripheral neuropathy (CIPN). Its lead candidate Halneuron is a NaV 1.7 sodium channel blocker in Phase 2b with FDA Fast Track designation, and SP16 IV is an LRP1 agonist peptide entering Phase 1b development under a royalty-free global license from Serpin Pharma.

Product overview

Dogwood Therapeutics is a development-stage biopharmaceutical company focused on developing first-in-class, non-opioid medicines to treat pain and neuropathic disorders. The proprietary pipeline includes two first-in-class development candidates: Halneuron, a NaV 1.7 sodium channel inhibitor in Phase 2b development for chemotherapy-induced neuropathic pain with FDA fast track designation, and SP16 IV, an LRP1 agonist peptide in Phase 1b development for chemotherapy-induced peripheral neuropathy. The company previously held antiviral assets IMC-1 (fibromyalgia) and IMC-2 (Long-COVID), which were licensed to PRIDCor Therapeutics in April 2026 for potential payments up to $100 million, allowing Dogwood to shift focus to its pain treatment pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Halneuron

Quantifiable outcome

• 4.3-4.5% dropout rate vs 20%+ for duloxetine and 30-40% for pregabalin in chronic pain medications
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered major and core.

• PRIDCor TherapeuticsmajorStrategic or Co-development Partner · 23 April 2026Global development and commercialization partnership for anti-viral candidates IMC-1 and IMC-2. PRIDCor receives full responsibility for development, commercialization, and IP maintenance. Dogwood entitled to tiered royalties up to 15% on net sales, 9% of future capital raised, and development/regulatory milestone payments. Potential total payments capped at $100 million.
• National Cancer Institute (NCI)coreStrategic or Co-development Partner · 15 April 2026$2.5 million National Cancer Institute grant fully funding Phase 1b clinical trial of SP16 at University of Virginia Cancer Center
• University of VirginiacoreImplementation/ SI/ Consulting Partner · 15 April 2026Phase 1b clinical trial for SP16 to be conducted at University of Virginia Cancer Center under leadership of Dr. Patrick Dillon, with patient enrollment expected mid-2026
• Serpin PharmacoreTechnology or Integration · 29 September 2025Exclusive royalty-free global license to develop Serpin Pharma's intravenous formulation of SP16 for chemotherapy-induced peripheral neuropathy. Dogwood issued Series A-2 preferred stock as consideration. Phase 1b trial fully funded by $2.5M NCI grant.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Lexicon Pharmaceuticals: Clinical-stage biotech developing LX9211 (a non-opioid analgesic) for chemotherapy-induced neuropathic pain, directly competing with Dogwood's Halneuron in the same CINP indication with similar mechanism differentiation.
• Tonix Pharmaceuticals: Specialty CNS biopharma developing TNX-102 SL for fibromyalgia and other CNS/pain indications; comparable clinical-stage pain pipeline targeting similar unmet needs as Dogwood's legacy IMC-1 program.
• Cara Therapeutics: Late-stage specialty pharma developing difelikefalin (Korsuva), an opioid-sparing therapy for pruritus and pain in chronic conditions; comparable clinical/commercial pain specialty focus and stage.
• Heron Therapeutics: Specialty oncology-supportive-care pharma with approved CINV products; comparable focus on improving chemotherapy patient outcomes (CINV/pain) and similar distribution channel strategy into oncology centers.
• Trevena Inc. Clinical-stage pain biopharma developing novel CNS-targeted analgesics, including OLINVYK (already approved IV opioid); comparable clinical-stage pain pipeline targeting non-opioid or specialty positioning.

Broad incumbents

• Vertex Pharmaceuticals: Large biopharma that developed and commercialized VX-548, a non-opioid NaV 1.8 inhibitor for acute pain; relevant historical comparator in the NaV channel pain space where Dogwood's Halneuron also operates.
• Collegium Pharmaceutical: Established specialty pain pharma with a portfolio including abuse-deterrent opioids; comparable pain specialty commercialization model that Dogwood plans to adopt post-approval.
• Pfizer: Large pharma that has historically pursued CIPN/CINP programs (e.g., tanezumab); relevant comparator as a potential acquirer or competitive threat given scope and resources in neuropathic pain.

Emerging players

• Algo Therapeutics: Emerging clinical-stage developer of non-opioid pain therapies with mechanism overlap to Halneuron's NaV 1.7 focus; potential competing pipeline entrant in the same indication space.
• Hyloris Pharmaceuticals: Specialty pharma focused on reformulated and repurposed pain/CNS therapeutics; comparable development-stage profile and specialty commercialization model targeting unmet pain indications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/intent/tweet?url=https://www.dwtx.com
• Facebookfacebook.com/sharer/sharer.php?u=https://www.dwtx.com
• LinkedInlinkedin.com/shareArticle?mini=true&url=https://www.dwtx.com

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries5 records

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dogwood Therapeutics